2. Anti-infection
  3. Antibiotic Parasite
  4. Alazopeptin

Alazopeptin is a non-ribosomal tripeptide azoamino acid antibiotic isolated from various Streptomyces species, with significant anti-tumor, antibacterial and trypanocidal activities. Alazopeptin exhibits cytotoxicity against mouse leukemia cells and S-180 tumor cells, inhibits the growth of Bacillus subtilis, and shows activity against Trypanosoma brucei. Alazopeptin can be widely used in studies related to mouse leukemia, S-180 tumor, human African trypanosomiasis and nagana.

For research use only. We do not sell to patients.

Alazopeptin

Alazopeptin Chemical Structure

CAS No. : 1397-84-8

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Alazopeptin Related Antibodies

Top Publications Citing Use of Products

View All Antibiotic Isoform Specific Products:

View All Isoforms
Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

View All Parasite Isoform Specific Products:

View All Isoforms
Amebae Coccidia Leishmania Mite Plasmodium Toxoplasma Trypanosoma Schistosome

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Alazopeptin is a non-ribosomal tripeptide azoamino acid antibiotic isolated from various Streptomyces species, with significant anti-tumor, antibacterial and trypanocidal activities. Alazopeptin exhibits cytotoxicity against mouse leukemia cells and S-180 tumor cells, inhibits the growth of Bacillus subtilis, and shows activity against Trypanosoma brucei. Alazopeptin can be widely used in studies related to mouse leukemia, S-180 tumor, human African trypanosomiasis and nagana[1][2][3][4].

IC50 & Target[1]

Trypanosoma

 

In Vitro

Alazopeptin exhibits moderate in vitro antitrypanosomal activity and low cytotoxicity against Trypanosoma brucei brucei strain GUTat 3.1 and Trypanosoma brucei rhodesiense strain STIB900[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Alazopeptin Related Antibodies

Cell Cytotoxicity Assay[2]

Cell Line: Trypanosoma brucei brucei strain and Trypanosoma brucei rhodesiense strain STIB900
Concentration: IC50
Incubation Time: 72 h
Result: Exhibied Trypanosoma brucei brucei strain GUTat 3.1 (IC50=0.51 μg/mL) and Trypanosoma brucei rhodesiense strain STIB900 (IC50=1.21 μg/mL), with low cytotoxicity against human MRC-5 cells (IC50 >9.10 μg/mL).
In Vivo

Alazopeptin (1.8-57.3 mg/kg; i.p.; daily; until death) dose-dependently prolongs survival in CDF1 mice with L-1210 leukemia, reaching a maximum average response of 287% at a daily intraperitoneal dose of 57.3 mg/kg[3].
Alazopeptin (4.5-36.4 mg/kg; i.v.; daily; 7-10 days) dose-dependently inhibits S-180 solid tumor growth in dd mice[3].
Alazopeptin shows no detectable efficacy against Ehrlich ascites carcinoma in dd mice[3].
Alazopeptin (50 mg/kg; i.p.; daily; 4 consecutive days) does not cure T. b. brucei S427 infection in female ICR mice but increases mean survival day by 1.8-fold relative to controls[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: CDF1 mice with Leukemia (~20 g)[3]
Dosage: 57.3 mg/kg/day; 28.7 mg/kg/day; 14.3 mg/kg/day; 7.2 mg/kg/day; 3.6 mg/kg/day; 1.8 mg/kg/day
Administration: i.p.; daily; until death
Result: Achieved a mean survival time (MST) T/C of 23.0/8.0 days, corresponding to an average response of 287% at 57.3 mg/kg/day, with all 6 mice surviving.
Achieved an MST T/C of 16.0/8.0 days (average response 200%) at 28.7 mg/kg/day, with all 6 mice surviving.
Achieved an MST T/C of 14.0/8.0 days (average response 175%) at 14.3 mg/kg/day, with all 6 mice surviving.
Achieved an MST T/C of 13.0/8.0 days (average response 163%) at 7.2 mg/kg/day, with all 6 mice surviving.
Achieved an MST T/C of 11.0/8.0 days (average response 138%) at 3.6 mg/kg/day, with all 6 mice surviving.
Achieved an MST T/C of 8.5/8.0 days (average response 107%) at 1.8 mg/kg/day, with all 6 mice surviving.
Showed better efficacy with daily administration than intermittent administration every 2 days.
Animal Model: dd mice with Sarcoma[3]
Dosage: 36.4 mg/kg/day (days 1-10); 18.2 mg/kg/day (days 1-10); 9.1 mg/kg/day (days 1-10); 4.5 mg/kg/day (days 1-10); 36.4 mg/kg/day (days 5-11); 18.2 mg/kg/day (days 5-11); 9.1 mg/kg/day (days 5-11); 4.5 mg/kg/day (days 5-11)
Administration: i.v.; daily; 10 days (days 1-10); 7 days (days 5-11)
Result: Achieved 100% tumor weight inhibition (tumor weight 0 mg vs control 1401 mg) at 36.4 mg/kg/day (days 1-10), with all 10 mice surviving.
Achieved 99% tumor weight inhibition (tumor weight 8 mg vs control 1401 mg) at 18.2 mg/kg/day (days 1-10), with all 10 mice surviving.
Achieved 89% tumor weight inhibition (tumor weight 158 mg vs control 1401 mg) at 9.1 mg/kg/day (days 1-10), with all 10 mice surviving.
Achieved 21% tumor weight inhibition (tumor weight 1102 mg vs control 1401 mg) at 4.5 mg/kg/day (days 1-10), with all 10 mice surviving.
Achieved 97% tumor weight inhibition (tumor weight 73 mg vs control 2500 mg) at 36.4 mg/kg/day (days 5-11), with all 10 mice surviving.
Achieved 90% tumor weight inhibition (tumor weight 259 mg vs control 2500 mg) at 18.2 mg/kg/day (days 5-11), with all 10 mice surviving.
Achieved 77% tumor weight inhibition (tumor weight 568 mg vs control 2500 mg) at 9.1 mg/kg/day (days 5-11), with all 10 mice surviving.
Achieved 25% tumor weight inhibition (tumor weight 1870 mg vs control 2500 mg) at 4.5 mg/kg/day (days 5-11), with all 10 mice surviving.
Exhibited marked antitumor activity when treatment started 5 days post-transplantation.
Molecular Weight

364.36

Formula

C15H20N6O5
CAS No.
SMILES

O=C(O)[C@H](CCC(C=[N+]=[N-])=O)NC([C@H](CCC(C=[N+]=[N-])=O)NCC=C)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Alazopeptin Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Alazopeptin1397-84-8AntibioticParasiteStreptacidiphilus griseoplanusS-180 tumor cellsBacillus subtilisEhrlich ascites carcinomaStreptomyces candidus var. azaticusKitasatospora azaticahuman MRC-5 cellsTrypanosoma brucei bruceimouse leukemia L-1210Trypanosoma brucei rhodesienseInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Alazopeptin
Cat. No.:
HY-118965
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.